ClinicalTrials.gg
Status unknownNCT03236636Updated Jan 27, 2021

The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma Subjects

A Phase 3 interventional study of Icaritin and HUACHANSU PIAN in Advanced HBV-Related Hepatocellular Carcinoma (HCC), sponsored by Beijing Shenogen Biomedical Co., Ltd. Status unknown at 28 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-27.

Sponsored by Beijing Shenogen Biomedical Co., Ltd · Phase 3, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Jan 2021), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
312
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,314 studies in Carcinoma, Hepatocellular with a site in China — 489 open to participants now, 561 under way, 70 of them phase 3. Carcinoma, Hepatocellular · China.

Planned enrollment
133rd of 1,038
312 · median 77
Started
2017
with 49 others
Phase 3
169 of 1,314
40 open now
Registered
305th of 1,314
by date

Among the 1,314 studies in Carcinoma, Hepatocellular with a site in China, this one is the 133rd largest by planned enrollment of the 1,038 interventional ones that give a count, is one of 50 that started in 2017, is one of 169 in phase 3, and was the 305th registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

489 of the 1,314 studies in Carcinoma, Hepatocellular with a site in China are open now. Recruiting first, the newest first:

484 more — sign in →

All 489 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,314 studies in Carcinoma, Hepatocellular with a site in China, or all of them as a file.
02

Study summary

The enriched HBV-related advanced HCC patient population (composite biomarker score ≥ 2) and overall survival (OS) were compared between the two groups.

Read the detailed description

The basis of enrichment design adjustment : The latest published literature shows that the heterogeneity and immune tolerance of patients with hepatitis B virus (HBV) - related HCC are significantly correlated with a number of cytokines, including helper T cell subgroup 1 / 2 (Th1 / Th2) related factors. Moreover, the accumulated data show that the immunomodulatory effect of flavonoids including Icaritin is related to Th1 / Th2 factors. At the same time, the recent REACH2 study published in Lancet Oncology has successfully used serum alpha fetoprotein (AFP≥400) to enrich patients with advanced HCC. Based on the updated published data and our phase II clinical trial data, considering that the ongoing clinical trials are still in a blind state and no statistical analysis has been conducted, with consulting of clinical experts, regulatory agency advice, the protocol was amended and approved into adaptive enrichment design. Before unblended and SAP, the amendment protocol was prospectively pre-defined including sample size, patient population (CBS score positive), and event number for interim and final analysis. combined with the latest FDA clinical trial enrichment design guidelines (2019), several experts recommended to use the composite biomarkers, including IFN-γ , TNF - α and AFP, which may demonstrate the clinical advantages of the immunomodulation therapy with Icaritin for HBV-related advanced HCC patients in China with poor prognosis, but currently lack of treatment options.

Definition of enriched HBV-related advanced HCC patient:

Patient with serum composite biomarker score (CBS)≥2

Enrichment design amendment:

Based on our previous phase II data of Icaritin collected from HBV-related advanced HCC patients and the related literature, we assume that the mOS of the enriched population (CBS≥2) is 420 days (14 months) in the experimental group and 240 days (8 months) in the HUACHASHU control group; the HR of the experimental group relative to the control group is 0.57. A total of 106 target death events and 130 evaluable subjects were required for the enrichment. Once the amendment protocol be effective, the enriched and non-enriched patients will be continuously randomized into the experimental and the control arms accordingly (1:1). When the number of enrolled cases reaches 280, or 60% of events (64) of 106 deaths has been observed in the enriched population, interim analysis will be performed.

03

Conditions studied

  • Advanced HBV-Related Hepatocellular Carcinoma (HCC)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Only patients who meet all the following criteria are included in the study:

    1. Age≥18years, no gender restriction; 2) Advanced or HCC patients in strict compliance with the "Primary Liver Cancer Diagnosis and Treatment Standard" (2017 Edition) issued by the National Health and Family Planning Commission, clinical diagnostic criteria and/or diagnosed by pathology /cytology, patients who fail to undergo liver surgery and/or other local treatment (ablation or hepatic artery intervention), or patients who have recurrence and progression after surgery and/or other local treatment; 3) Not previously accepted system therapy (systemic chemotherapy, molecular targeting, immunotherapy and research medication, etc.) for advanced or metastatic HCC, including but not limited to systematic chemotherapy with oxaliplatin, sorafenib, /PD-L1 antibody, Icaritin and cinobufotalin, etc.; 4) Liver surgery was performed more than 3 months ago, ablation or interventional treatment of hepatic artery was performed more than 4 weeks ago, and the adverse reactions returned to normal; After surgery or other local treatment, if patients have gone beyond the norm for systemic chemotherapy, it will need more than 6 months after the chemotherapy, and disease progression and / or metastasis have occurred; 5) For patients who are not suitable for first-line treatment of advanced HCC which is recommended in "Primary Liver Cancer Diagnosis and Treatment Standard." issued by the National Health and Family Planning Commission, it's mainly due to partial blood test indicators (See the relaxed scope in 11th inclusion criteria ) or other indicators (Including mild ascites and so on) which are not suitable for the existing first-line standard treatment; Or in particular cases, the patients insist on refusing to accept the existing first-line standard treatment(For example, patients feel that their physical condition is weak and / or economic constraints, which must be strictly mastered and controlled); 6) 2 weeks before the first medication of the trial, there is no use of modern Chinese medicine preparation with liver cancer indication, including Delisheng injection, Kanglaite injection or soft capsule, Aidi injection or Considi injection, elemene injection/oral liquid, 1) 7) no use of blood transfusion or blood products, no use of hematopoietic stimulating factor, no transfusion of albumin or blood products 14 days before screening; 8) According to the evaluation criteria of solid tumor reaction ( 1.1), it has at least one measurable target lesion, which defined as non-lymph node lesions with the longest diameter larger than 10mm, lymph node lesions with the short diameter larger than 15mm; the lesions previously received local treatment such as ablation or hepatic artery interventional therapy should be detected by computed tomography (CT) / magnetic resonance imaging (MRI) and according to RECIST1.1, It's sure that disease progression has occurred and the longest diameter is more than 1.0cm,it can be used as a measurable target lesions; 9) The score of liver function is grade A or better grade B (score≤7); 10) The score of physical condition is 0-1; 11) Expected survival time≥12 weeks; 12) The function of the main organs is basically normal and meets the following requirements:

    ①Marrow: There is no blood transfusion and use of hematopoietic cell stimulating agent, including granulocyte colony stimulating factor (G-CSF)within 14 days before screening, ≥60×10E9/L, ≥ 85g/L, white blood cell≥3.0×10E9/L; After a thorough measurement of the patient's condition, the above three items can be appropriately relaxed by the principal researchers at the research centre as: platelet 50 \~60×10E9/L, hemoglobin 80\~85g/L, white blood cell 2.5 \~3.0×10E9/L (contains critical values);

    ②Liver: Total ≤1.5 times of the (ULN), (AST) and alanine aminotransferase (ALT)≤5 × ULN; albumin≥ 28g/L;

    ④ Kidney: Serum creatinine≤ 1.5 x ULN, or rate≥ 50ml/min; 13) If ≥104 copies/ml(2000IU/ml), antiviral therapy must be done first, the patient can be included in the group until HBV-DNA\<104 copies /ml(2000IU/ml); and continue to take antiviral drugs, monitor liver function and hepatitis B virus load; 14) Women of childbearing age must receive pregnancy tests 14 days before treatment and the results are negative; Men of childbearing age need effective during treatment and within 3 months after treatment; 15) Patients are volunteered to join the study, sign the , have good compliance and cooperate with follow-up; 16) The subjects do not participate in other clinical trials within 4 weeks before screening; If the subject fails in other test screening, but meets the requirements of this test, then can be enrolled.

Exclusion criteria

Exclusion Criteria:

  • Patients who meet any of the following criteria are not allowed to enter the test:

    1. Imaging examination shows that HCC liver tumors are huge (≥60% of the liver volume), or cancer embolus of portal trunk (occupying ≥50% of the vascular diameter), or cancer embolus invading mesenteric vein or inferior vena cava;
    2. Middle or higher ascites which is , it requires therapeutic abdominal paracentesis /drainage, or the score > 2;
    3. Local anticancer therapy (including surgery, ablation, hepatic arterial chemotherapy, embolization or radiotherapy) or major surgery was performed 28 days prior to randomization;
    4. Hepatocholangiocarcinoma and fibrolamellar cell carcinoma; In the past 5 years or at the same time, there were other , except cervical carcinoma in situ, previously treated basal cell carcinoma and superficial bladder tumor (Ta, Tis, T1);
    5. Pregnant or lactating women;
    6. The patient suffers from classification type II or above myocardial ischemia or myocardial infarction, poorly controlled arrhythmia; and/or standard III to IV cardiac dysfunction.
    7. Allograft transplants including liver transplantation were performed previously, or a liver transplant was planned during the trial;
    8. Hepatic encephalopathy and / or hepatic nephropathy occurred within 6 months;
    9. Patient with active , that is, anti -HCV positive or HCV-RNA positive and abnormal liver function;
    10. (HIV) tests are positive or severe infection requiring systemic treatment with antibiotics;
    11. Inability to swallow, chronic diarrhea or intestinal obstruction that significantly affecting medication intake and absorption;
    12. Having a history of digestive tract bleeding within 6 months, or with a clear gastrointestinal bleeding tendency, including local active ulcerative lesions, positive fecal occult blood;
    13. The patient has or is suspected to have known active disease;
    14. If a central nervous system is known and a metastasis of the central nervous system is suspected, the cranial MRI examination should be performed to exclude it;
    15. Abnormal coagulation function: (INR) >1.5 or prothrombin time (PT) >16S;
    16. There is a history of schizophrenia or psychotropic substance abuse;
    17. Known to be allergic or intolerant to Icaritin or cinobufotalin and ;
    18. Other conditions that researchers believe discourage patients from participating in trials.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
312 participants (estimated)

Study arms

  • Experimental
    Icaritin

    Icaritin:600mg/time, 6 capsules/time(6×100mg/capsule), 2 times/day(30 minutes after breakfast, lunch and dinner), take orally, continuous administration until reach the standard of termination.

    Drug: Icaritin

  • Active comparator
    HUACHANSU PIAN

    HUANCHANSU PIAN:Take orally 4 tablets/time(0.3g/tablet), 3 times/day(30 minutes after breakfast, lunch and dinner), continuous administration until reach the standard of termination.

    Drug: HUACHANSU PIAN

Interventions

  • Icaritin:600mg/time, 6 capsules/time(6×100mg/capsule), 2 times/day(30 minutes after breakfast, lunch and dinner), take orally, continuous administration until reach the standard of termination.

    Also known as: SNG-162

  • DrugHUACHANSU PIAN

    HUACHANSU PIAN:Take orally 4 tablets/time(0.3g/tablet), 3 times/day(30 minutes after breakfast, lunch and dinner), continuous administration until reach the standard of termination.

    Also known as: HUACHANSU PIAN(999)

06

What researchers measure

Primary outcomes

  1. Overall survival (OS)

    OS is defined as the time from randomization to died from any cause. For the subjects who failed to visit, deletion is performed on the final date of knowing the survival of the subjects, for subjects who still survive, deletion is performed on the data expiration date.

    Time frame: 2-4 years

Secondary outcomes

  1. Progression-free survival (PFS)

    PFS is defined as the date from randomization to the first radiographic record of disease progression or death (whichever occurs first). See the Statistical Analysis Plan (SAP) for the definition of PFS deletion rule.

    Time frame: 2-3 years

  2. Time to progress(TTP)

    TTP is defined as the date from randomization to the first radiographic record of disease progression, see the Statistical Analysis Plan(SAP) for the definition of TTP deletion rule.

    Time frame: 2-3 years

  3. Overall response rate (ORR)

    ORR is defined as the proportion of subjects achieving optimal overall efficacy such as CR or partial remission (PR).

    Time frame: 2-3 years

  4. Overall disease control rate (DCR)

    DCR is defined as the proportion of subjects achieving optimal overall efficacy such as CR, PR or stable disease (SD).

    Time frame: 2-3 years

  5. Assessment on Quality of life 1

    Quality of life (QOL) changes: Quality of life scores are assessed with EORTC QLQ-C30 and compared with baseline values.

    Time frame: 2-4 years

  6. Assessment on Quality of life 2

    Quality of life (QOL) changes: Quality of life scores are assessed with EORTCQLQ-HCC-18 and compared with baseline values.

    Time frame: 2-4 years

Other outcomes

  1. Biomarker analysis of proteome level (Immunohistochemical method)

    Baseline expression or expression changes of programmed cell death ligand 1 (PD-L1), heterogeneous ribonucleoprotein A2/B1 (hnRNPAB1) and interleukin -6 (IL-6) and so on.

    Time frame: 2-4 years

  2. Genome level (DNA, mRNA, miRNA) biomarker analysis

    Genetic variation(Liver cancer driver genes and hotspot gene mutations, such as IDH1/2, JAK2/3, PD-L1/2), expression levels of oncogenes and immune related genes(Gene copy number and RNA expression level) and epigenetics cohort analysis

    Time frame: 2-4 years

07

Study locations

27 of 28 sites recruiting
  • Anhui Provincial Hospital
    Hefei, Anhui, China
    Recruiting
    • Yueyin Pan · Contact
    • Yueyin Pan · Principal investigator
  • The First Affiliated Hospital of Anhui Medical University
    Hefei, Anhui, China
    Recruiting
    • Kangsheng Gu · Contact
    • Kangsheng Gu · Principal investigator
  • Cancer Hospital Chinese Academy of Medical Sciences
    Beijing, Beijing 100021, China
    Recruiting
    • Chengxu Cui, MD · Contact13701212251@139.com · +86 010-87788120
    • Chengxu Cui, MD · Principal investigator
  • Beijing Hospital
    Beijing, Beijing, China
    Recruiting
    • Yunbo Zhao · Contact
    • Yunbo Zhao · Principal investigator
  • General Hospital of Chinese Armed Police Forces
    Beijing, Beijing, China
    Terminated
  • Guang'anmen Hospital of China Academy of Chinese Medical Sciences
    Beijing, Beijing, China
    Recruiting
    • Wei Hou · Contact
    • Wei Hou · Principal investigator
  • Peking University Cancer Hospital
    Beijing, Beijing, China
    Recruiting
    • Chunyi Hao · Contact
    • Chunyi Hao · Principal investigator
  • Chongqing Traditional Chinese Medicine Hospital
    Chongqing, Chongqing, China
    Recruiting
    • Lingzhan Meng · Contact
    • Lingzhan Meng · Principal investigator
  • The First People's Hospital of Foshan
    Foshan, Guangdong, China
    Recruiting
    • Bin Hu · Contact
    • Bin Hu · Principal investigator
  • Affiliated Hospital of Guilin Medical University
    Guilin, Guangxi, China
    Recruiting
    • Qian Chen · Contact
    • Qian Chen · Principal investigator
  • Guangxi Medical University Affiliated Tumor Hospital
    Nanning, Guangxi, China
    Recruiting
    • Bangde Xiang · Contact
    • Bangde Xiang · Principal investigator
  • Haikou People's Hospital
    Haikou, Hainan, China
    Recruiting
    • Juan Meng · Contact
    • Juan Meng · Principal investigator
  • The Fourth Hospital of Hebei Medical University
    Shijiazhuang, Hebei, China
    Recruiting
    • Ruixing Zhang · Contact
    • Ruixing Zhang · Principal investigator
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan, China
    Recruiting
    • Wang Ma · Contact
    • Wang Ma · Principal investigator
  • The Third Xiangya Hospital of Central South University
    Changsha, Hunan, China
    Recruiting
    • Peiguo Cao · Contact
    • Peiguo Cao · Principal investigator
  • Eastern Theater General Hospital,QinHuai District Medical Area
    Nanjing, Jiangsu 210002, China
    Recruiting
    • Shukui Qin, MD · Contactqinsk@csco.org.cn · 025-84453932
    • Shukui Qin, MD · Principal investigator
  • The First Affiliated Hospital with Nanjing Medical University
    Nanjing, Jiangsu, China
    Recruiting
    • Yongqian Su · Contact
    • Yongqian Su · Principal investigator
  • The Affiliated Tumor Hospital of Nantong University
    Nantong, Jiangsu, China
    Recruiting
    • Aibing Xu · Contact
    • Aibing Xu · Principal investigator
  • First Hospital of Jilin University
    Changchun, Jilin, China
    Recruiting
    • Wei Li · Contact
    • Wei Li · Principal investigator
  • The Sixth People's Hospital in Shenyang
    Shenyang, Liaoning, China
    Recruiting
    • Wei Wu · Contact
    • Wei Wu · Principal investigator
  • Chifeng Municipal Hospital
    Chifeng, Neimenggu, China
    Recruiting
    • Hongbo Ji · Contact
    • Hongbo Ji · Principal investigator
  • Jinan Central Hospital
    Jinan, Shandong, China
    Recruiting
    • Yuping Sun · Contact
    • Yuping Sun · Principal investigator
  • Linyi Cancer Hospital
    Linyi, Shandong, China
    Recruiting
    • Jianhua Shi · Contact
    • Jianhua Shi · Principal investigator
  • Fudan University Shanghai Cancer Center
    Shanghai, Shanghai, China
    Recruiting
    • Zhiqiang Meng · Contact
    • Zhiqiang Meng · Principal investigator
  • West China Hospital of Sichuan University
    Chengdu, Sichuan, China
    Recruiting
    • Ying Zhang · Contact
    • Ying Zhang · Principal investigator
  • Yunnan Provincial Hospital of Traditional Chinese Medicine
    Kunming, Yunnan, China
    Recruiting
    • Yi Li · Contact
    • Yi Li · Principal investigator
  • The Affiliated Hospital of Hangzhou Normal University
    Hangzhou, Zhejiang, China
    Recruiting
    • Gongying Chen · Contact
    • Gongying Chen · Principal investigator
  • Nanfang Hospital of Southern Medical University
    Guangzhou, China
    Recruiting
    • Yabing Guo · Contact
    • Yabing Guo · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2017 (actual). Primary completion is estimated for Dec 2022, 63 months after the start.

Of 53 industry-sponsored phase 3 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 63. This study's planned 63 months is above that.

Counting every sponsor, half of 139 studies reached it within 56 months; a quarter within 43 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2017
First posted
Aug 2, 2017
StartActual
Sep 8, 2017
Primary completionEst.
Dec 30, 2022
CompletionEst.
Dec 30, 2022
Last update
Jan 27, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03236636
Lead sponsor
Beijing Shenogen Biomedical Co., Ltd
Collaborators
Chinese Academy of Medical Sciences, NanJing PLA 81 Hospital, Peking University Cancer Hospital & Institute, Beijing Hospital, Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Jinan Central Hospital, Linyi Tumour Hospital, The First Affiliated Hospital of Anhui Medical University, Anhui Provincial Hospital, The First Affiliated Hospital with Nanjing Medical University, The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China, Nanfang Hospital, Southern Medical University, First People's Hospital of Foshan, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Hebei Medical University Fourth Hospital, The First Hospital of Jilin University, Haikou People's Hospital, Fudan University, West China Hospital, Chongqing Traditional Chinese Medicine Hospital, Chifeng Municipal Hospital, The Affiliated Hospital of Hangzhou Normal University, The First Affiliated Hospital of Zhengzhou University, Guilin Medical University, China, The Third Xiangya Hospital of Central South University, Yunnan Provincial Hospital of Traditional Chinese Medicine, The Sixth People's Hospital of Shenyang
Responsible party
Sponsor
First posted
Aug 2, 2017
Start date
Sep 8, 2017
Primary completion
Dec 30, 2022 (estimated)
Completion
Dec 30, 2022 (estimated)
Last update
Jan 27, 2021

Study contacts

Yan Sun, MD
Contact
suny@csco.org.cn
+86 10 67781331
Shukui Qin
Contact
qinsk@csco.org.cn
+86 25 80864806
Yan Sun, MD
principal investigator · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Shukui Qin
principal investigator · NanJing PLA 81 Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Icaritin

Start the discussion